Topical bacteriocin therapy with epidermicin NI01 for dermatological infections (TOBRADERM)
使用表皮霉素 NI01 局部细菌素治疗皮肤感染 (TOBRADERM)
基本信息
- 批准号:10071961
- 负责人:
- 金额:$ 89.04万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Collaborative R&D
- 财政年份:2024
- 资助国家:英国
- 起止时间:2024 至 无数据
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Amprologix is a company developing novel antibiotics to meet the global threat of antimicrobial resistance (AMR). AMR happens when bacteria become resistant to antibiotics and results in treatment failure and increased death from 'drug resistant' infections. These infections killed over 1.2 million people in 2019 and new antibiotics are urgently needed. If we don't develop new antibiotics, our current medical system may fail and things like cancer therapy and routine surgery may result in a fatal infection.In this TOBRADERM project, Amprologix will test a new antibiotic compound, epidermicin NI01, for treating skin infections, which affect millions of people every year in the UK and are the cause of more than 10% of all antibiotic prescriptions. Skin infections can be minor but can also result in severe and fatal outcomes, and they are increasingly complicated by AMR. We will develop epidermicin to be used externally (topical application), being applied directly to infected areas. This increases the killing action but also helps preserve current antibiotics, taken orally or by injection, for use against serious infections, like those in the blood.Epidermicin NI01 is from a new class of antibiotic compound, the bacteriocins (small protein-like molecules). Whilst bacteriocins are not used to treat patients yet, epidermicin has many features that increase the chance of it being a successful drug. These features include properties that minimise any risks that have stopped development of previous bacteriocins: it has very potent activity against globally leading pathogens ('superbugs'), including those that are resistant to current antibiotics and the leading causes of skin infections; toxicity is extremely low, even in recent safety tests in animals; resistance is very unlikely to occur due to the novel way it kills target bacteria; and we have developed an extremely low-cost production system. Epidermicin will also not kill all kinds of bacteria meaning it will target the main pathogens, leaving other skin bacteria unharmed, protecting the 'microbiome'.Epidermicin is an extremely promising new antibiotic and success in the TOBRADERM project will allow Amprologix to access new drug markets, helping it grow into a global leader in 'topical therapeutics'. This will create jobs, generate income for the company and enable development of a new drug to treat skin infections, potentially benefitting over 1 million people a year in the UK.
Amprologix是一家开发新型抗生素的公司,以应对全球抗菌素耐药性(AMR)的威胁。当细菌对抗生素产生抗药性,导致治疗失败,并增加因“耐药”感染而死亡时,就会发生AMR。2019年,这些感染导致120多万人死亡,迫切需要新的抗生素。如果我们不开发新的抗生素,我们现有的医疗系统可能会失败,癌症治疗和常规手术可能会导致致命的感染。在这个TOBRADERM项目中,Amprologix将测试一种新的抗生素化合物,表皮霉素NI01,用于治疗皮肤感染。在英国,皮肤感染每年影响数百万人,占所有抗生素处方的10%以上。皮肤感染可能很轻微,但也可能导致严重和致命的后果,而且AMR使皮肤感染越来越复杂。我们将开发外用(局部使用)的表皮霉素,直接应用于感染部位。这增加了杀灭作用,但也有助于保存目前的抗生素,口服或注射,用于治疗严重感染,如血液中的感染。表皮霉素NI01来自一种新的抗生素化合物,细菌素(类蛋白质小分子)。虽然细菌素还没有被用于治疗患者,但表皮霉素具有许多特性,可以增加它成为成功药物的机会。这些特性包括将阻止以前细菌素发展的任何风险降至最低的特性:它对全球领先的病原体(“超级细菌”)具有非常强的活性,包括那些对当前抗生素具有抗药性的病原体和导致皮肤感染的主要原因;毒性极低,即使在最近的动物安全测试中也是如此;由于它杀死目标细菌的新颖方式,抗药性极不可能发生;我们已经开发了一种极低成本的生产系统。表德米星也不会杀死所有类型的细菌,这意味着它将针对主要病原体,使其他皮肤细菌不受伤害,保护“微生物群”。表德米星是一种非常有前途的新抗生素,TOBRADERM项目的成功将使Amprologix进入新药市场,帮助它成长为“局部治疗”领域的全球领先者。这将创造就业机会,为公司创造收入,并使治疗皮肤感染的新药得以开发,每年可能使英国100多万人受益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
其他文献
吉治仁志 他: "トランスジェニックマウスによるTIMP-1の線維化促進機序"最新医学. 55. 1781-1787 (2000)
Hitoshi Yoshiji 等:“转基因小鼠中 TIMP-1 的促纤维化机制”现代医学 55. 1781-1787 (2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
LiDAR Implementations for Autonomous Vehicle Applications
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
吉治仁志 他: "イラスト医学&サイエンスシリーズ血管の分子医学"羊土社(渋谷正史編). 125 (2000)
Hitoshi Yoshiji 等人:“血管医学与科学系列分子医学图解”Yodosha(涉谷正志编辑)125(2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Effect of manidipine hydrochloride,a calcium antagonist,on isoproterenol-induced left ventricular hypertrophy: "Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,K.,Teragaki,M.,Iwao,H.and Yoshikawa,J." Jpn Circ J. 62(1). 47-52 (1998)
钙拮抗剂盐酸马尼地平对异丙肾上腺素引起的左心室肥厚的影响:“Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('', 18)}}的其他基金
An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
- 批准号:
2901954 - 财政年份:2028
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
- 批准号:
2896097 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
- 批准号:
2780268 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
- 批准号:
2908918 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
- 批准号:
2908693 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
- 批准号:
2908917 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
- 批准号:
2879438 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
- 批准号:
2879865 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
- 批准号:
2890513 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
- 批准号:
2876993 - 财政年份:2027
- 资助金额:
$ 89.04万 - 项目类别:
Studentship
相似海外基金
Oral microbiome and inflammatory status in antimicrobially-treated oral cancer patients
接受抗菌药物治疗的口腔癌患者的口腔微生物组和炎症状态
- 批准号:
10642765 - 财政年份:2022
- 资助金额:
$ 89.04万 - 项目类别:
Oral microbiome and inflammatory status in antimicrobially-treated oral cancer patients
接受抗菌药物治疗的口腔癌患者的口腔微生物组和炎症状态
- 批准号:
10685029 - 财政年份:2022
- 资助金额:
$ 89.04万 - 项目类别:
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
项目 3:从共生到病原体转变的功能微生物组和宿主特征
- 批准号:
10614695 - 财政年份:2020
- 资助金额:
$ 89.04万 - 项目类别:
Probiotics that moderate pH and antagonize pathogens to promote oral health
益生菌可调节 pH 值并对抗病原体,促进口腔健康
- 批准号:
10175495 - 财政年份:2020
- 资助金额:
$ 89.04万 - 项目类别:
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
项目 3:从共生到病原体转变的功能微生物组和宿主特征
- 批准号:
10226289 - 财政年份:2020
- 资助金额:
$ 89.04万 - 项目类别:
Project 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogen
项目 3:从共生到病原体转变的功能微生物组和宿主特征
- 批准号:
10024961 - 财政年份:2020
- 资助金额:
$ 89.04万 - 项目类别:
Temporal dynamics of MDRO eradication after FMT
FMT 后 MDRO 根除的时间动态
- 批准号:
10378130 - 财政年份:2019
- 资助金额:
$ 89.04万 - 项目类别:
Temporal dynamics of MDRO eradication after FMT
FMT 后 MDRO 根除的时间动态
- 批准号:
10598519 - 财政年份:2019
- 资助金额:
$ 89.04万 - 项目类别:
Co-opting Endogenous Pathogen Autolysins as Next Generation Antibiotics
选择内源性病原体自溶素作为下一代抗生素
- 批准号:
10053699 - 财政年份:2016
- 资助金额:
$ 89.04万 - 项目类别:
Development of a Probiotic Therapy for Limiting Group B Streptococcal Vaginal Carriage
开发用于限制 B 族链球菌阴道携带的益生菌疗法
- 批准号:
9522750 - 财政年份:2016
- 资助金额:
$ 89.04万 - 项目类别: